Showing results (11-20 of 71) with videos related to
Sort By:
Pageof 8
Rheumatology (Oxford, England)|September 16, 2021
Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosusYen Lin Chia, Jianchun Zhang, Raj Tummala, et al.Molecular Medicine (Cambridge, Mass.)|October 23, 2003
Diversification of the Ig variable region gene repertoire of synovial B lymphocytes by nucleotide insertion and deletionYasushi Miura, Charles C Chu, David M Dines, et al.Arthritis and Rheumatism|August 1, 2008
Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trialMario H Cardiel, James A Tumlin, Richard A Furie, et al.Rheumatology and Therapy|March 9, 2021
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus ErythematosusAnca D Askanase, George J Wan, Mary P Panaccio, et al.Lupus Science & Medicine|February 18, 2021
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trialsRaj Tummala, Gabriel Abreu, Lilia Pineda, et al.Arthritis & Rheumatology (Hoboken, N.J.)|February 7, 2018
Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United StatesRichard A Furie, Daniel J Wallace, Cynthia Aranow, et al.The Lancet. Rheumatology|January 30, 2024
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trialsEric F Morand, Richard A Furie, Ian N Bruce, et al.The Lancet. Rheumatology|January 30, 2024
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumabVibeke Strand, Sean O'Quinn, Richard A Furie, et al.Lupus Science & Medicine|October 23, 2021
Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosusErik W Anderson, Joanna Fishbein, Joseph Hong, et al.Journal of Clinical Pharmacology|March 30, 2022
Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus ErythematosusYen Lin Chia, Raj Tummala, Tu H Mai, et al.Pageof 8